Resmed completed its acquisition of Noctrix Health, expanding its clinical sleep-health portfolio. Noctrix develops non-invasive peripheral nerve stimulation for restless legs syndrome, an indication with limited device-based options. The deal, announced in April, places a focused neuromodulation therapy inside a large sleep and respiratory platform with established procurement and distribution reach. Alongside the deal, Resmed announced a partnership with Oura, opening its network to Ring wearers.